Assessing Cardiac Safety in Phase I

Cardiac safety issues are among the most common reasons for promising drugs to be halted in development and failing to launch. So why wait to see if there’s a potential problem?

Learn how clinical trial sponsors who conduct QT assessments during Phase I can harness the power of early knowledge to better inform their development decisions while saving considerable time and money.

Read the full article here.

Share